Key result
In silico screening and experimental validation identified three compounds with promising antiviral activity against SARS-CoV-2, with the most promising candidate showing an EC50 of 5.04 µM.
Population
SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) in silico and in vitro models
Design
Preclinical
Authors
Loading...
May guide antiviral lead optimization; leaves open clinical translation pending in vivo and human validation.
In silico screening and experimental validation identified three novel compounds with promising antiviral activity against SARS-CoV-2 RdRp, providing a foundation for developing new lead compounds.
Uengwetwanit et al. (2022) studied SARS-CoV-2. SARS-CoV-2 RdRp inhibitors was evaluated on Antiviral activity (half-maximal effective concentration, EC50). In silico screening and experimental validation identified three compounds with promising antiviral activity against SARS-CoV-2, with the most promising candidate showing an EC50 of 5.04 µM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: